BERKELEY, Calif., May 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , a biopharmaceutical company focused on developing therapies for cardiovascular disease, is pleased to announce the appointment of Jane Moffitt, J.D., LL.M. as its Vice President of Regulatory Affairs.
“We believe Jane’s specific leadership contribution to the launch and development of natriuretic peptide BNP, Natrecor(R), plus her extensive regulatory affairs background will be of great value to Nile as we develop our own natriuretic peptide, CD-NP and cardiovascular pipeline,” said Peter Strumph, Chief Executive Officer of Nile.
Ms. Moffitt has over 30 years of professional experience in regulatory affairs and corporate and food & drug law for pharmaceutical, device and biotechnology companies. This experience includes developing clinical regulatory strategies and leading teams responsible for preparing and maintaining INDs, NDAs, BLAs and global product launches. Her drug product expertise includes natriuretic peptides, small molecules and biologics.
Prior to joining Nile, Ms. Moffitt was the West Coast Director of Operations for SciLucent, a specialty healthcare-focused consulting firm. Prior to that, Jane was a Senior Vice President of Quality and Regulatory Affairs at a number of pharmaceutical and medical device companies, including Revance Therapeutics Inc., Scios, Inc., Collagen Corporation, and Amsco International Inc., and worked as a corporate attorney at Miles Laboratories, Inc. At Scios, Ms. Moffitt was a member of the Corporate Management Committee, started the Government Affairs function and was the head of the regulatory affairs function. Ms. Moffitt also served as President, Treasurer and a member of the Board of Directors of Scios R&D, Inc. and BRP, Inc.
Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson College, a J.D. from Dickinson School of Law and a LL.M. in Trade Regulation from New York University School of Law.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric natriuretic peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company’s strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at www.nilethera.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile’s product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the “Risk Factors” section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Daron Evans, Chief Financial Officer, Nile Therapeutics, Inc.,
+1-415-875-7882, info@nilethera.com
Web site: http://www.nilethera.com/
